Participated · Series C · Apr 2026

E2 is commercializing the Hēlo® Thrombectomy Platform, designed with a patented dual-action mechanism that integrates aspiration with mechanical clot disruption to deliver large-bore performance through a small-profile catheter. The system is indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature and supports injection, infusion, and aspiration during procedures. E2 describes the platform as intended to improve procedural efficiency and clinical performance as mechanical thrombectomy adoption grows. With the oversubscribed $80 million Series C, the company plans to scale its commercial organization and continue investments in research and operations. The company is backed by a syndicate including Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. New board members from the lead investors will join as the company advances commercialization.

Participated · Seed · Dec 2025

DISCO Pharmaceuticals is an oncology biotech leveraging a proprietary platform that maps the entire cell surface (the surfaceome) to uncover novel target pairs for drug development. Using these discoveries, the company engineers highly selective bispecific antibody-drug conjugates (ADCs) and T-cell engagers aimed at indications such as small cell lung cancer and microsatellite-stable colorectal cancer. The technology is designed to broaden the universe of actionable cancer targets and improve therapeutic precision. Recently, DISCO appointed veteran oncology executive Mark Manfredi, Ph.D., as CEO, while founder Roman Thomas, M.D., transitioned to a strategic advisor role. With a total of €36 million in seed capital, the company plans to move multiple lead ADC candidates into IND-enabling studies and to expand both indication-specific and pan-tumor programs. Investors believe the platform can unlock entirely new therapeutic areas by revealing previously unknown cell-surface biology. The fresh capital provides runway to advance the lead programs toward the clinic and continue generating additional surfaceome-based targets.

Participated · Series A · Oct 2025

Founded in 2022 as a spin-off of Italy’s National Research Council (CNR), NanoPhoria Bioscience is building a versatile nano-in-micro delivery platform that transports inorganic calcium-phosphate nanoparticles from the lungs directly to the heart. Its lead candidate, NP-MP1, is a first-in-class peptide that targets cardiac L-type calcium channels to enhance ejection fraction in patients suffering from heart failure with reduced ejection fraction (HFrEF). Pre-clinical studies have demonstrated strong efficacy, and the company plans to advance NP-MP1 through IND-enabling studies, early clinical development, GMP scale-up and regulatory programs. Beyond HFrEF, the firm intends to apply its platform to additional cardiovascular and chronic disease indications that are underserved by existing treatments. NanoPhoria has attracted significant investor support, closing an €83.5 million Series A round—the largest ever for an Italian biotech—led by XGEN Venture, Sofinnova Partners, CDP Venture Capital, and Panakès Partners. This capital provides the runway to progress NP-MP1 into the clinic and expand the internal pipeline. The firm has not yet disclosed revenue or patient numbers, reflecting its pre-commercial stage. With a robust syndicate and proprietary delivery technology, NanoPhoria aims to redefine treatment paradigms in cardiovascular medicine.

Participated · Series B · May 2025

Salvia BioElectronics is developing MySalvia Therapy, an implantable neuromodulation system aimed at reducing the frequency and severity of chronic migraine attacks. The system uses two ultra-thin implants placed under the skin of the forehead and back of the head, activated on demand by an external wearable device, and is designed to be patient-controlled and minimally invasive. Salvia holds FDA Breakthrough Device Designation and is conducting the multi-center, double-blind, sham-controlled RECLAIM trial in Europe and Australia, with U.S. trials planned. The company says its approach targets patients who have not responded well to conventional therapies, addressing a large unmet need given migraine's substantial economic and disability burden. Salvia plans to use new capital to complete the RECLAIM study, pursue regulatory filings, and prepare for commercial launches in the United States, Europe, and Australia. It recently closed a $60M Series B to support those efforts, backed by a syndicate of investors. Salvia BioElectronics develops a neuromodulation platform that uses highly conforming bioelectronic foils designed to be inserted below the skin in a minimally invasive procedure to target known neural targets in chronic migraine. The company aims to translate proven neurostimulation therapy into an implantable form factor that is compatible with head anatomy, with the ambition of delivering a therapy as easy as taking medication and side-effect free. Salvia was founded in 2017 by neuromodulation industry veterans and is based in Eindhoven, the Netherlands. The startup emphasizes safety, effectiveness, affordability, and completing therapy development toward market entry. Management positions the approach as addressing an unmet need because there are currently no approved implantable devices for chronic migraine despite neurostimulation’s demonstrated effectiveness. The recent financing provides capital to advance product development and regulatory progress toward commercialization.

Led · Series C · Apr 2025

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.